198 related articles for article (PubMed ID: 36629968)
1. Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden.
Ngwenya S; Simin J; Brusselaers N
Dig Dis Sci; 2023 Jun; 68(6):2252-2263. PubMed ID: 36629968
[TBL] [Abstract][Full Text] [Related]
2. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
Brusselaers N; Wahlin K; Engstrand L; Lagergren J
BMJ Open; 2017 Oct; 7(10):e017739. PubMed ID: 29084798
[TBL] [Abstract][Full Text] [Related]
3. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors and risk of all-cause and cause-specific mortality: A cohort study.
Brown JP; Tazare JR; Williamson E; Mansfield KE; Evans SJ; Tomlinson LA; Bhaskaran K; Smeeth L; Wing K; Douglas IJ
Br J Clin Pharmacol; 2021 Aug; 87(8):3150-3161. PubMed ID: 33393677
[TBL] [Abstract][Full Text] [Related]
5. Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study.
Kim B; Jung JH; Han K; Kang S; Lee E; Chung H; Kim SG; Cho SJ
J Korean Med Sci; 2023 Apr; 38(13):e99. PubMed ID: 37012686
[TBL] [Abstract][Full Text] [Related]
6. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden.
Brusselaers N; Sadr-Azodi O; Engstrand L
J Gastroenterol; 2020 Apr; 55(4):453-461. PubMed ID: 31811561
[TBL] [Abstract][Full Text] [Related]
7. Proton Pump Inhibitor Use, H
Paik JM; Rosen HN; Gordon CM; Curhan GC
Calcif Tissue Int; 2018 Oct; 103(4):380-387. PubMed ID: 29754277
[TBL] [Abstract][Full Text] [Related]
8. Proton pump inhibitor use and risk of pneumonia: a self-controlled case series study.
Maret-Ouda J; Panula J; Santoni G; Xie S; Lagergren J
J Gastroenterol; 2023 Aug; 58(8):734-740. PubMed ID: 37314495
[TBL] [Abstract][Full Text] [Related]
9. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
BMJ Open; 2017 Jul; 7(6):e015735. PubMed ID: 28676480
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study.
Kieboom BC; Kiefte-de Jong JC; Eijgelsheim M; Franco OH; Kuipers EJ; Hofman A; Zietse R; Stricker BH; Hoorn EJ
Am J Kidney Dis; 2015 Nov; 66(5):775-82. PubMed ID: 26123862
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors and chronic kidney disease risk: a comparative study with histamine-2 receptor antagonists.
Kweon T; Kim Y; Lee KJ; Seo WW; Seo SI; Shin WG; Shin DH
Sci Rep; 2023 Dec; 13(1):21169. PubMed ID: 38036592
[TBL] [Abstract][Full Text] [Related]
12. Clinical Use of Acid Suppressants and Risk of Dementia in the Elderly: A Pharmaco-Epidemiological Cohort Study.
Chen LY; Lin HJ; Wu WT; Chen YC; Chen CL; Kao J; You SL; Chou YC; Sun CA
Int J Environ Res Public Health; 2020 Nov; 17(21):. PubMed ID: 33182362
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study.
Poulsen AH; Christensen S; McLaughlin JK; Thomsen RW; Sørensen HT; Olsen JH; Friis S
Br J Cancer; 2009 May; 100(9):1503-7. PubMed ID: 19352380
[TBL] [Abstract][Full Text] [Related]
14. Comparative risk of incidence and clinical outcomes of COVID-19 among proton pump inhibitor and histamine-2 receptor antagonist short-term users: a nationwide retrospective cohort study.
Park J; You SC; Cho J; Park CH; Shin WG; Park RW; In Seo S
BMC Pharmacol Toxicol; 2022 Jan; 23(1):9. PubMed ID: 35039078
[TBL] [Abstract][Full Text] [Related]
15. Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.
Vangala C; Niu J; Lenihan CR; Mitch WE; Navaneethan SD; Winkelmayer WC
Clin J Am Soc Nephrol; 2018 Oct; 13(10):1534-1541. PubMed ID: 30262672
[TBL] [Abstract][Full Text] [Related]
16. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
[TBL] [Abstract][Full Text] [Related]
17. Proton Pump Inhibitor Use and Obesity-Associated Cancer in the Women's Health Initiative.
Ballinger TJ; Djuric Z; Sardesai S; Hovey KM; Andrews CA; Brasky TM; Zhang JT; Rohan TE; Saquib N; Shadyab AH; Simon M; Wactawski-Wende J; Wallace R; Kato I
Nutr Cancer; 2023; 75(1):265-275. PubMed ID: 35968582
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
Park JH; Song YM; Jung JH; Han K
Bone; 2020 Jun; 135():115306. PubMed ID: 32126312
[TBL] [Abstract][Full Text] [Related]
19. Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study.
Wei J; Chan AT; Zeng C; Bai X; Lu N; Lei G; Zhang Y
Bone; 2020 Oct; 139():115502. PubMed ID: 32593677
[TBL] [Abstract][Full Text] [Related]
20. Long-term continuous use of proton-pump inhibitors is associated with renal function decline in patients without acute kidney injury.
Hatakeyama Y; Horino T; Matsumoto T; Terada Y; Okuhara Y
Clin Exp Nephrol; 2021 Oct; 25(10):1087-1092. PubMed ID: 34089392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
